Immune checkpoint therapies, including anti-CTLA-4 and anti-PD-1 therapies, that block T cell inhibitory pathways have led to durable antitumor responses and clinical benefit in a substantial number of patients with cancer 1,2 . However, prostate cancer has proven to be poorly responsive to immune checkpoint monotherapy [3] [4] [5] . To better understand the immune profile within prostate tumors and potential compensatory immune inhibitory pathways that may arise in the setting of immune checkpoint monotherapy, we conducted a clinical trial (NCT01194271) with ipilimumab plus androgen-deprivation therapy (ADT) before surgery in patients with localized prostate cancer ( Supplementary Fig. 1a -c and Supplementary Tables 1 and 2) .
We compared post-treatment and baseline blood samples ( Supplementary Fig. 1a) , evaluating the levels of CD4 + and CD8 + T cells (Supplementary Fig. 2a) , as well as those of T cell subsets expressing inducible costimulator (ICOS), OX40, 4-1BB, PD-1, CTLA-4, and FoxP3 ( Supplementary Fig. 2a,b) . We observed an increase in CD4 + and CD8 + T cells, including PD-1 + and ICOS + subsets, after ipilimumab therapy, which is similar to our previous findings with ipilimumab monotherapy in patients with melanoma and bladder cancer [6] [7] [8] . We also compared post-treatment tumor tissues ( Supplementary Fig. 1a ) to those of stage-matched untreated tumors from another cohort of patients (Supplementary Fig. 1b) . Flow cytometric studies revealed a significantly higher frequency of CD4 + , CD8 + , and ICOS + T cells in the post-treatment tumors (Fig. 1a) . Immunohistochemical (IHC) studies also demonstrated significant increases in tumor-infiltrating immune cells, including CD4 + , CD8 + , ICOS + , CD45RO + , granzyme-B (GrB) + , and CD68 + cells (Supplementary Fig. 3 ). We found significantly greater immune cell infiltration in prostate tumors after ipilimumab therapy but not after ADT alone, although ADT monotherapy was associated with significantly higher levels of ICOS + and GrB + cells, which may represent an activated T cell subset (Fig. 1b) . Taken together, our data suggest that the immunologic changes in post-treatment tumors were mostly due to ipilimumab therapy, as opposed to ADT. However, we cannot discount a possible synergistic effect between ipilimumab and ADT.
We did not observe clinical responses consisting of pathologic complete response, as we did previously for patients with bladder cancer 8 . To identify potential mechanisms that might explain this lack of response, we performed an unbiased gene expression study and found that ipilimumab therapy resulted in significant changes in the expression of a total of 690 genes (false discovery rate (FDR) < 0.2; P < 0.028; log 2 (fold change) > 0.5)(Supplementary Table 3) , most of which are related to immune responses ( Supplementary  Fig. 4a ). We focused our analyses on a subset of genes that represent inhibitory immune checkpoints and identified increased PD-L1 and VISTA expression in post-treatment tumors ( Supplementary  Fig. 4b ). Both PD-L1 and VISTA were previously reported as inhibitory molecules that can suppress murine and human T cell responses 9,10 . Here we found significantly greater protein expression of PD-1, PD-L1, and VISTA in prostate tumors after ipilimumab therapy ( Fig. 1c and Supplementary Fig. 5a ).
We also evaluated metastatic tumors and blood samples from patients with metastatic prostate cancer who took part in a separate clinical trial (NCT02113657) and received treatment with ipilimumab, finding an increase in PD-L1 and VISTA expression in tumor tissues (Supplementary Fig. 5b ) as well as on monocytes in blood ( Supplementary Fig. 6a) , which was similar to data from a mouse model of prostate cancer (Supplementary Fig. 6b ). We suggest that PD-L1 and VISTA are likely to be relevant inhibitory immune checkpoints in both localized and metastatic prostate cancer.
We evaluated PD-L1 and VISTA expression in different cell subtypes from matched pre-and post-treatment prostate tumors and observed significantly higher PD-L1 expression on CD4 + T cells, CD8 + T cells, and CD68 + macrophages after treatment (Supplementary Fig. 7a ).
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
To date, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not been demonstrated to be of substantial clinical benefit in patients with prostate cancer. To identify additional immune-inhibitory pathways in the prostate-tumor microenvironment, we evaluated untreated and ipilimumabtreated tumors from patients in a presurgical clinical trial. Levels of the PD-L1 and VISTA inhibitory molecules increased on independent subsets of macrophages in treated tumors. Our data suggest that VISTA represents another compensatory inhibitory pathway in prostate tumors after ipilimumab therapy. 
On average, we observed an increase of approximately threefold (from 0.2% to 0.7%) in the percentage of CD4 + T cells expressing PD-L1 (Fig. 1d) . More strikingly, we observed an average increase of approximately fivefold (from 4.4% to 21.3%) in the percentage of CD8 + T cells expressing PD-L1 and an increase of approximately tenfold (from 2.5% to 25%) in the percentage of CD68 + macrophages expressing PD-L1 (Fig. 1d) . Also, we observed, on average, an increase of approximately 12-fold (from 1.8% to 21.5%) in the percentage of tumor cells with PD-L1 expression (Fig. 1d) .
Similarly, ipilimumab therapy resulted in significantly higher VISTA expression on CD4 + T cells, CD8 + T cells, and CD68 + macrophages (Supplementary Fig. 7b ). To our knowledge, this represents the first report of VISTA expression on T cells in human tumors 10 . VISTA expression was not observed on CD4 + and CD8 + T cells in tumor tissues prior to treatment, but was detected on approximately 4% of CD4 + T cells and 7% of CD8 + T cells after ipilimumab therapy (Fig. 1e) . The proportion of CD68 + macrophages with VISTA expression was observed to increase by approximately fourfold (from 7% to 31%) (Fig. 1e) .
Next, we compared stage-matched untreated and post-therapy prostate tumors with stage-matched untreated and post-therapy metastatic melanomas. We found that untreated melanomas had significantly higher levels of CD8 + T cells and CD68 + macrophages than untreated prostate tumors (P = 0.04 and P = 0.0005, respectively; Fig. 1f) . Post-treatment melanomas and prostate tumors both demonstrated an approximately 2-fold higher frequency of CD4 + T cells and an approximately 1.5-fold higher frequency of CD8 + T cells and CD68 + macrophages in comparison to respective stage-matched untreated tumors (Fig. 1f) . Our data indicate an increase in the percentage of T cells and tumor cells with PD-L1 expression in tissue from post-treatment tumors for both tumor types (Fig. 1g) . However, we found that there was a significantly greater proportion of CD68 + macrophages with PD-L1 expression in post-treatment prostate tumors in comparison to melanomas, with an approximately threefold increase in the percentage of CD68 + PD-L1 + macrophages in prostate tumors (Fig. 1g) . Since PD-L1 expression is known to be regulated by interferon (IFN)-γ and ipilimumab therapy is known to increase IFN-γ production by T cells 6,11 , we evaluated potential correlations between the expression of CD274 (PD-L1) and IFN-γ-responsive genes (IL15, IFNAR2, CXCL10, and IRF1), finding a high degree of correlation in post-treatment prostate tumors and melanomas (Supplementary Fig. 8) .
We also found a higher frequency of VISTA expression on T cells and CD68 + macrophages in post-treatment melanomas and prostate tumors as compared to their respective matched, pre-treatment tumors (Fig. 1h) . However, we found that there was a significantly greater proportion of CD68 + macrophages with VISTA expression in post-treatment prostate tumors as compared to melanomas, with an approximately fivefold higher frequency of CD68 + VISTA + macrophages in prostate tumors (Fig. 1h) . Unlike PD-L1, there was no correlation between C10orf54 (VISTA) expression and that of IFN-γ-responsive genes (Supplementary Table 4) .
We sought to determine whether PD-L1 and VISTA were coexpressed on CD68 + macrophages or if the cells expressing these proteins represented individual subsets of inhibitory cells in tissue from post-treatment prostate tumors (Fig. 2a) . We found that PD-L1 + CD68 + cells comprised about 29.4% of all CD68 + macrophages and VISTA + CD68 + cells had a similar frequency of 26.5%, whereas PD-L1 + VISTA + double-positive CD68 + cells comprised only 2% of the total CD68 + population in tissue from post-treatment tumors (Fig. 2b) . Cytometry by time of flight (CyTOF) analysis of fresh tumors from two patients who received ipilimumab therapy on a separate protocol (NCT02113657) also demonstrated PD-L1 and VISTA expression on predominantly distinct subsets of CD68 + macrophages (Supplementary Fig. 9 ).
Because macrophages can be classified into M1 and M2 subtypes, which function to promote antitumor responses and tumor growth, respectively 12 , we evaluated post-treatment prostate tumors and melanomas for changes in the expression of M1-like genes. We found a higher fold induction of M1-like genes in post-treatment melanomas than in post-treatment prostate tumors (Fig. 2c) . Additional studies demonstrated a significant increase (7.4-fold) in ARG1 expression (M2-like) in post-treatment prostate tumor tissues (Fig. 2d) . The ratio of ARG1 (M2-like) to iNOS (M1-like) changed from 1.4 to 3.6 in pre-treatment versus post-treatment tumors (Fig. 2d) . Furthermore, we found that there was a significant increase in the proportion of both CD68 + PD-L1 + and CD68 + VISTA + cells that expressed CD163 (M2-like) in post-treatment samples (Fig. 2e) . Overall, our data show an increase in the frequency of PD-L1 + and VISTA + macrophages with expression of CD163 and ARG1, suggesting an M2-like phenotype and function, respectively. In addition, plate-bound PD-L1 or VISTA protein in in vitro studies led to a significant decrease in the production of IFN-γ and tumor necrosis factor (TNF)-α by T cells from patients with prostate cancer (Fig. 2f) . In contrast, pre-treatment of monocytes with anti-VISTA antibody resulted in a significant reversal of monocyte-mediated suppression of IFN-γ production in T cells (Fig. 2g) .
The identification of multiple immune checkpoints within the immune system, such as PD-L1 and VISTA, indicates the importance of understanding the expression of these molecules within the tumor microenvironment in order to design rational combinationtreatment strategies. Our data suggest that anti-CTLA-4 therapy can enhance immune cell infiltration into tumors, including in prostate cancer. These data highlight the importance of obtaining longitudinal tumor tissues while patients are receiving treatment, possibly after two doses of therapy, to identify the immunologic changes that occur in the tumor microenvironment. Our data suggest that an increase in immune cell infiltration may be insufficient to generate antitumor responses; a blockade of other immune checkpoints, such as PD1/PD-L1 and/or VISTA, may be necessary to provide substantial clinical benefit for patients with prostate cancer. To our knowledge, our data represent the first finding of VISTA as a compensatory inhibitory pathway in the setting of ipilimumab therapy in prostate cancer, but future studies will need to elucidate the role of VISTA as a potential resistance mechanism and determine whether VISTA can be targeted to improve antitumor responses in patients.
(Please see the Supplementary Discussion for extended discussion.)
MeThODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Fig. 1a) . Optional biopsies of tumor tissues were collected before treatment, and tumor tissues were then collected at the time of surgery for immune monitoring studies. Blood was also collected before each therapeutic intervention for immune monitoring studies. A total of 20 patients were evaluated for this trial. Patients 2 and 20 failed to meet eligibility criteria and patient 14 withdrew from consent before treatment; the other 17 patients received ADT plus ipilimumab treatment and completed analyses for safety. Of these 17 patients, 16 completed surgery. One patient died of a cardiac complication before surgery 13 . All 17 patients experienced some type of immune-related adverse event (irAE); however, grade 3 or 4 irAEs occurred in 8/17 patients and consisted of colitis/ diarrhea, hypophysitis, pancreatitis, and transaminitis (Supplementary Table 2) , which were treated with corticosteroids and other immune-suppressive agents as previously described 13 . Only two patients (patients 15 and 16) experienced grade 3 or 4 irAE before surgery, which required high-dose corticosteroids with subsequent delay of surgery. We did not observe any surgical or post-operative complications as a result of treatment in the clinical trial. Of the 16 patients, 6 developed biochemically recurrent disease as measured by elevated blood prostate-specific antigen (PSA) levels. Among these six patients with biochemical recurrence, three were found to have detectable metastatic disease on imaging studies. Ten patients were noted to remain without any evidence of disease for at least 3.5 years. One patient was lost to follow-up and 15 of 16 patients remained alive 3.5 years after completion of the last surgery as of November 2016. Healthy donor blood and additional tissue samples from untreated patients with localized prostate cancer (Supplementary Fig. 1b ) and ADT-treated prostatectomy samples (Supplementary Fig. 1c 
IHC.
For IHC, primary antibodies were used to detect CD4 (Novocastra, CD4-368-l-A; 1:80), CD8 (Thermo Scientific, MS-457-S; 1:25), CD45RO (Novocastra, PA0146; 3:4), GrB (Leica Microsystems, PA0291, RTU), ICOS (Spring Bioscience, M3980; 1:100), CD68 (Dako, M0876; 1:450), PD-L1 (Cell Signaling, 13684S; 1:100), PD-1 (Epitomicsm, Abcam, ab137132; 1:250), arginase-1 (Cell Signaling, 93668; 1:100), iNOS (Abcam, ab95866; 1:500), and VISTA (proprietary antibody from Janssen; 1:100). Slides were scanned and digitalized using the Scanscope system (Scanscope XT, Aperio/Leica). Quantitative analyses of IHC staining were conducted using image analysis software (ImageScope-Aperio/Leica). Five random areas (of at least 1 mm 2 each) were selected, and a customized algorithm specific to each marker was used for quantification (percentage of positive cells). Only samples that had more than 1% tumor cells present in the sample were used for analyses. Two pathologists (I.I.W. and J.B.) performed an independent review of the IHC and immunofluorescence data. PD-L1 staining was carried out as described previously 14 . Representative images for positive and negative controls that were analyzed for the VISTA antibody are shown in Supplementary Figure 10 . VISTA antibody development and validation were performed according to Janssen's patent description at https://patentscope.wipo. int/search/en/detail.jsf?docId=WO2015097536. The K562 parental human leukemia cell line (Supplementary Fig. 10a ) was used as a negative control; a VISTA-transfected K562 cell line (Supplementary Fig. 10b ) and human tonsil tissue (Supplementary Fig. 10c ) were used as positive controls for our studies and demonstrated cell surface staining (Supplementary Fig. 10d ). The anti-VISTA antibody used for our IHC studies was obtained from Janssen and will be available via a material transfer agreement between interested researchers and Janssen. Each primary antibody used has been validated for the relevant species and applications according to the manufacturer's website.
Multiplex immunofluorescence assays and multispectral analysis. Multiplex staining was performed per the Opal protocol staining method 15 for the following markers: CD4 (1:25; CM153BK, Biocare) with subsequent visualization using fluorescein AF-488 (1:50); CD8 (1:200; M7103, Dako) with visualization using AF-594 (1:50); CD68 (1:100; M0876, Dako) with visualization using AF-647; VISTA (1:100; Janssen) with visualization using coumarin (1:50); CD163 (1:100; NCL-L-CD163, Leica) with visualization using AF-488 (1:50); and PD-L1 (1:100; 13684, Cell Signaling Technology) with visualization using AF-555 (1:50). Nuclei were visualized with DAPI (1:2,000). All sections were coverslipped using Vectashield Hardset 895 mounting media. For multispectral analysis, each individually stained section (CD4/AF-488, CD8/AF-594, CD68/AX-647, VISTA/coumarin, PD-L1/AF-555, CD163/AF-488, and DAPI) was used to establish the spectral library of fluorophores. Slides were scanned using the Vectra slide scanner (PerkinElmer). For each marker, the mean fluorescent intensity per case was determined as a base point from which positive calls could be established. The colocalization algorithm was used to determine the percentage of PD-L1 and VISTA staining on each cellular subset. Five random areas on each sample were analyzed with blinding to sample identity by a pathologist at 20× magnification.
CyTOF. Fresh metastatic prostate tumor samples were used for the CyTOF analysis. The tumor samples were dissociated with the GentleMACS system (Miltenyi Biotec; Bergisch Gladbach, Germany) and cultured overnight in RPMI complete medium. The cells were then collected and stained with 36 analytes, including CD68, PD-L1, VISTA, CD70, Foxp3, BTLA, 41BBL, ICOSL, CD80, B7-H4, CTLA-4, CD3, TIM-3, CD27, CD86, PD-1, CD28, KI67, 41BB, TIGIT, CD73, CD4, CD8, OX40, CD326, ICOS, LAG3, galectin-9, HVEM, B7-H3, CD45, GITR, PD-L2, OX40L, HLA-DR, and CD56. The data were analyzed using the ViSNE program 16 and the Phenograph algorithm 17 programs.
Flow cytometry analysis.
Fresh peripheral blood mononuclear cell (PBMC) preparation, generation of single-cell tumor suspensions (≥100,000 total cells at different time points), and multiparameter flow cytometric analysis of T cell subsets for CD4, CD8, ICOS, Foxp3, ICOS (BioLegend, CA), PD-1 (BioLegend, CA), 4-1BB, OX40, CTLA-4, CD14 (eBioscience, CA), CD16 (BD Biosciences, CA), PD-L1 (BD Biosciences, CA), and VISTA (kindly provided by Janssen, CA) were carried out as we previously reported 6 .
Microarray and nanostring analyses. Pre-therapy and post-therapy prostate tumor samples were collected to undergo total RNA isolation using the Qiagen RNeasy Mini Kit. Total RNA was used for Affymetrix GeneChip Human Gene 1.0 ST Array analysis. Microarray data were preprocessed using the aroma. affymetrix Bioconductor package. Background correction and quantile normalization were performed using robust multi-chip average. A two-sample Welch t-test was used to compare the gene expression of the pre-therapy and posttherapy groups. The beta-uniform mixture model was used to fit the P-value distribution for multiple-testing adjustments. Pathway analysis was performed using IPA (Ingenuity Pathway Analysis) (Redwood City, CA). The Pearson correlation was calculated for PD-L1 and each IFN-response gene in both melanomas and prostate tumor tissues.
In vitro human T cell function analyses. PBMCs from seven patients with prostate cancer who received ipilimumab on protocol NCT02113657 were used for these studies. Briefly, 96-well plates were coated overnight with 2.5 µg/ml anti-CD3 (BD Bioscience) together with Fc fusion proteins: 10 µg/ml VISTA Ig (R&D Systems), 10 µg/ml PD-L1 Ig (R&D Systems), 10 µg/ml control Ig (R&D Systems), or a VISTA/PD-L1 Ig combination. CD3 + T cells were plated at 2 × 10 5 cells per well in complete TCCM medium (IMDM with human AB serum (5%), penicillin-streptomycin, HEPES, 2-mercaptoethanol, and gentamicin) and incubated for 48 h. The supernatants were collected after 48 h, and cytokines (IFN-γ and TNF-α) were measured using the Mesoscale Discovery system (Rockville, MD).
For coculture studies, blood samples were obtained from two patients treated with ipilimumab. A total of 100,000 purified CD3 + T cells were cultured with or without 500,000 CD14 + monocytes in each well in triplicate in 96-well plates. Fifty microliters of anti-CD3 antibody (0.5 µg/ml) was added to each well for
